“…According to Baran et al, low- and high-risk mutations account for approximately 50% and 30% of malignant pediatric nodules, respectively, while the remaining cases harbor relatively uncommon variants (APC, BLM, PPM1D mutations, FGFR1 rearrangements) which require further investigation [ 46 ]. In addition, they observed a correlation between the Bethesda category and the presence of high-risk genetic alterations, opening the possibility of creating an effective cytological and molecular combined algorithm of risk classification, as previously performed with ultrasound and FNA [ 1 , 19 , 46 ]. DICER1 mutations seem to correlate with the macrofollicular variant of FTC, in which have been found in up to 50% of cases, and seem to be involved in the progression from FTC to PDTC [ 10 ].…”